Pfizer Announces
Transthyretin Cardiac Amyloidosis Fellowship
Competitive Grant Program

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP). Institutions are invited to submit an application as outlined in the specific RFP.

This RFP reflects Pfizer’s commitment to advancing research, innovation, and training for medical, nursing, and allied health professionals.
## II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>United States with interest in supporting both established and emerging Amyloid Centers of Excellence</th>
</tr>
</thead>
</table>

### Applicant Eligibility Criteria
- Accredited, US-based academic institution.
- Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.
- Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required.
- No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.
- Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.
  - Examples of research that would **not** be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).
- Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions.
- Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.

## III. Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>January 6, 2020</th>
</tr>
</thead>
</table>

### Specific Area of Interest for this RFP
- It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.

### Requirements for Prospective Fellows:
- Institution must ensure that any fellow that will receive grant funds must be a U.S. Worker (U.S. citizen, permanent resident, refugee, or asylee), or hold an appropriate non-immigrant visa status authorizing employment in the U.S.
- U.S. Physician Payments Sunshine Act (“Sunshine Act”) and other transparency law requirements must be satisfied with respect to meals, payments and other transfers of value. As a condition of the grant, the
selected fellow will be named in transparency reporting as a recipient of grant funding.

**Budget:**
- Grant funding is available to support one fellow for up to a year at $80,000. The budget can include salary and support of the fellow benefits. There is a total budget of $240,000 for this program.
- Grant funds cannot be used for overhead or indirect costs.
- Funding will be awarded to the institution, not an individual.
- Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.
- No aspect of the fellowship program budget can reflect a benefit to Pfizer's business or a Pfizer asset.

**Key Dates:**
- RFP release date: January 6, 2020
- Full Proposal Deadline: *June 29, 2020
  
  *Please note the deadline is midnight Eastern Time (New York, GMT -5).*
- Review of Full Proposals by External Review Panel: July 2020
- Anticipated Full Proposal Notification Date: August 5, 2020
- Grants distributed following execution of fully signed Letter of Agreement
- Anticipated Project Start and End Dates: July 2021 to June 2022

**How to Submit:**
- Please go to [www.cybergrants.com/pfizer/GMGFellowship](http://www.cybergrants.com/pfizer/GMGFellowship) and sign in. First-time users should click “REGISTER NOW”.
- Select the following Competitive Grant Program Name: 2020 RD L – Cardiac Amyloidosis Fellowship U.S.
- Requirements for submission:
  - Complete all required sections of the online application
  - Upload Proposal (see Appendix).
  - Upload Budget file
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**Questions:**
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with
the subject line “ Transthyretin Cardiac Amyloidosis Fellowship

| Review and Approval Process | • A specific grant program RFP uses an external review panel (ERP) to make final grant decisions.  
|                           | • The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement |
| Mechanism by which Applicants will be Notified: | • All applicants will be notified via email by the dates noted above.  
|                                                   | • Applicants may be asked for additional clarification during the review period. |
IV. Terms and Conditions

1. This grant opportunity does not commit Pfizer to award a grant nor to pay any costs incurred in the preparation of a response to this RFP or any other expenses.

2. Pfizer reserves the right to accept or reject any or all applications received as a result of this RFP, or to cancel this grant opportunity in part or in its entirety at any time, if it determines it is in the best interest of Pfizer to do so.

3. For compliance reasons and in fairness to all applicants, all communications about this grant opportunity must be submitted exclusively to Pfizer GMG. Failure to comply will disqualify applicants.

4. Consistent with its commitment to openness and transparency, Pfizer discloses grants provided to medical, scientific, and academic institutions in accordance with applicable laws, regulations, and requirements. Pfizer reserves the right to publicly share the details of any successful grant application(s) by whatever means, including but not limited to the Pfizer website, in external presentations, and/or in other public media.

5. To ensure compliance with applicable local law, Pfizer may publicly disclose the support it provides. Pfizer may disclose in any lawful manner the terms of the letter of agreement, the support or funding that Pfizer is providing under the letter of agreement, and any other related information, to the extent necessary for Pfizer to meet its obligations under those laws, regulations and industry codes that require Pfizer to report payments or other transfers of value to certain healthcare professionals and teaching hospitals (collectively, the “Transparency Laws”). Transparency Laws include, without limitation, section 6002 of the U.S. Affordable Care Act and the EFPIA Code on Disclosure of Transfers of Value. Disclosures may include identifying information for organizations and U.S. physicians, such as name, business address, specialty, National Provider Identifier (NPI), and licensure numbers. Grantee will agree to (and will cause other agents, employees and contractors to) reasonably cooperate with Pfizer in Pfizer’s collection and disclosure of information to fulfill its Transparency Law obligations. Grantee will provide Pfizer with complete and accurate information about payments or other transfers of value reportable under Transparency Laws.

# Appendix A

## Proposal Requirements

The proposal should be submitted in Word or a PDF. This document should be formatted with single-spaced using 12-point font and 1-inch margins and should not exceed 10-15 pages.

### Cover Page (not to exceed 1 page)
- Title: Please include the fellowship title, and main institutions
- Abstract: Please include an abstract summary of your proposal including the goal of the fellowship, methods the institution uses to support the fellow’s training and research, and assessment.

### Overall Goals and Objectives of the Fellowship
- Describe the overall goal of the fellowship.
- Describe the focus of research and/or clinical training as applicable that is being supported in general terms based on the categorizations listed in this application.

### Methods
- Please describe the mentoring process.
- Include a description of the methods used to support the fellow and their research and/or clinical training.

### Resources
- Please describe the institution’s academic, clinical training, and research capacity.
- Describe the facilities/resources that are made available to the fellow.
- Provide a summary of relevant past work that is applicable.

### Challenges
- Please provide a summary of potential challenges and of plans for addressing those challenges.

### Institutional Support
- Division Head/Department Chair Letter of Support.
- Primary mentor; Secondary mentor (if applicable) Letter of Support.

### Budget
- Budget: Address any additional sources of financial support for this proposal, including current and pending sources of funding.
- Any request for funds beyond salary support will not be provided as part of the award.

### Anticipated Project Timeline
- Provide an anticipated timeline for your project including project start/end dates.
Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

Budget Requirements

The budget should be submitted in Excel. There is no page limit.